Offtheshelf

Biomedical engineers at Duke University have developed an entirely new approach to building point-of-care diagnostic devices that only use gravity to transport, mix and otherwise manipulate…

<!-- Name:DistributionId Value:8845791 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

When bacteria interact, they give off cellular signals that can trigger a response in their neighbors, causing them to behave in different ways or produce different substances. For example,…

An investigational, off-the-shelf T-cell therapy appears to be effective against six…

SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU)…

Co-authors on "Why Crypto-detectors Fail" are (from left) Nathan Cooper, Adwait Nadkarni, Amit Seal Ami, Kaushal Kafle…

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a…

5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients…

Immunotherapies, which harness the body's natural defenses to combat disease, have revolutionized the treatment of aggressive and deadly cancers. But often, these therapies -- especially…

10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in…